Clinical development of targeted and immune based anti-cancer therapies

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Cancer is a leading global cause of death, necessitating innovative treatments.
• Advances in understanding cancer's molecular pathways have enabled targeted therapies.
• Targeted therapies offer a promising alternative to traditional treatments with potentially better outcomes.

Purpose of the Study:

• To review the clinical development of targeted anti-cancer therapies.
• To discuss the successes and challenges associated with these novel treatments.
• To highlight specific targeted therapies including small molecule inhibitors and antibody-based treatments.

Main Methods:

• Review of clinical data and research on targeted anti-cancer therapies.
• Exploration of molecular targets such as epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and human epidermal growth factor receptor 2 (HER2).
• Examination of immunotherapies targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein-1 (PD-1)/PD-1 ligand (PD-1 L).

Main Results:

• Targeted therapies demonstrate specificity in blocking molecules crucial for cancer cell growth and tumorigenesis.
• These therapies show potential for enhanced efficacy and reduced adverse effects compared to conventional treatments.
• Specific examples include inhibitors for EGFR, VEGF, HER2, ALK, BRAF, CTLA-4, and PD-1/PD-1 L.

Conclusions:

• Targeted therapies represent a significant advancement in anti-cancer medicine.
• Continued research and clinical development are crucial to overcome challenges and maximize the benefits of these treatments.
• The specificity of targeted therapies holds promise for more personalized and effective cancer care.